THC Lags Peers as Options Hit Two-Year Defensiveness High

Tenet Healthcare has fallen 3.8% over the past week, a sharp contrast to the median gain of 3.2% across its closest hospital peers. UHS added 1.9% and HCA gained 2.3% over the same period, while Ardent Health rose 4.2%. THC is the clear underperformer in a group that is otherwise moving higher into the sector's earnings window.

Options positioning has turned markedly more defensive than it was when the last preview was published four days ago. The put/call ratio has climbed further to 1.00, now running 2.6 standard deviations above its 20-day average of 0.92. That is the most pronounced demand for downside protection seen on this name in months. The shift is notable because the lending market is still telling the opposite story: short interest edged up 11% over the past week but remains low at 2.2% of the free float, and availability is vast at more than 3,500% of short interest. Borrowing costs, while up roughly 28% on the week, are still only 0.34%. Shorts are not driving this; the defensiveness is concentrated in the options market.

The debate between the two camps centers on whether Tenet's USPI ambulatory surgery segment can carry enough margin momentum to offset structural headwinds in the Acute hospital business. The bull case points to USPI's faster growth, higher margins and improving payer mix, with analysts at Guggenheim and Leerink carrying targets of $307 and $309 respectively. The bear case is harder to dismiss: the anticipated expiration of ACA subsidies threatens to strip coverage from 80 to 85% of a specific patient cohort, with analysts modelling a potential $220 million headwind to the Acute segment and a $30 million drag on USPI itself in 2026. A $148 million non-recurring Medicaid state fund payment that boosted the most recent quarter only sharpens that scrutiny. The mean analyst target of $286 implies roughly 9% upside from current levels, but BMO's September initiation at Market Perform with a $265 target sits almost exactly where the stock is trading now.

The insider register adds a note of caution that has not shifted since the last preview. Over the 90 days to mid-September, insiders sold a net $50 million of stock in open-market transactions, none conducted under a pre-arranged 10b5-1 plan. The CEO sold nearly $13.7 million across three tranches on August 25, and the COO followed with $6.4 million on August 31. Director Richard Mark sold $2.6 million on September 10. T. Rowe Price remains the largest institutional holder at 10.9% of shares, having added just over one million shares in the most recent quarter, a counterweight worth noting alongside the executive selling.

Wednesday's print will test whether USPI's margin trajectory is strong enough to sustain the stock's 41% year-to-date rally at a time when its closest peers are climbing and THC alone is pulling back.